Scott Leftwich - 09 Jul 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role: Director
Signature: /s/ Andrew Jackson, Attorney-in-fact
Issuer symbol: CLDI
Transactions as of: 09 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 15 Jul 2025, 20:42:54 UTC
Previous filing: 03 Jan 2025
Next filing: 25 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Leftwich Scott	Director	C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,	/s/ Andrew Jackson, Attorney-in-fact	15 Jul 2025	0001991668

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLDI	Non-Qualified Stock Options (right to buy)	Award	$0	+137,078		$0.000000	137,078	09 Jul 2025	Common Stock	137,078	$0.7000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the "Options") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

Content

On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the "Options") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

Remarks:

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 4 dated July 2, 2024.)